Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX‐02 in Patients With Nephropathic Cystinosis

The aim of this study was to assess the pharmacokinetics (PK) and safety of ELX‐02 in a renally impaired population and apply these findings to the individualized dosing of patients with nephropathic cystinosis. This phase 1 renal impairment (RI; mild, moderate, or severe), single‐dose, PK, and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Haverty, Thomas, Wyatt, David J., Porter, Kaela M., Leubitz, Andi, Banks, Kate, Goodyer, Paul, Hu, Ming‐Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248099/
https://www.ncbi.nlm.nih.gov/pubmed/33355924
http://dx.doi.org/10.1002/jcph.1807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248099/
https://www.ncbi.nlm.nih.gov/pubmed/33355924
http://dx.doi.org/10.1002/jcph.1807

Ejemplares similares